Disclosure Information
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty has the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter | Reported Financial Relationship |
Bassam A. Bassam, MD, FAAN | Speaker’s Bureau: Argenx Pharmaceuticals |
Gregory Bergey, FANA, FAAN, FAES | Nothing to disclose |
Amy Brown, MD, MS | Contracted Research: Teva Pharmaceuticals, Neurocrine Biosciences, Alterity Therapeutics, PTC Therapeutics, Novartis, F. Hoffmann-La Roche, Sage Therapeutics, Abbvie Pharmaceuticals Honoraria: Open Health; M-Panels; InCrowd |
Cherylee Chang, MD | Nothing to disclose |
Larry Charleston, IV, MD, MSc, FAHS | Consulting Fee: Allergan/AbbVie, Alder/Lundbeck, Amneal, Biohaven, Haleon, Satsuma and Teva Contracted Research: Disparities in Headache Advisory Council, Amgen Honoraria: American Headache Society, American Academy of Neurology, BrainWeekend, NeurologyWeek, Migraine360 CME Program Stock Option Holder: Was on the advisory panel for Ctrl M Health (stock) – now defunct |
Ciaran Considine, PhD, ABPP-CN | Nothing to disclose |
Richard Ryan Darby, MD | Nothing to disclose |
Mazen Dimachkie, MD | Consulting Fee: Abcuro, Amazentis, ArgenX, Astellas, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, MDA, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma and UpToDate. Contracted Research: Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma/RaPharma, Viromed/Healixmith & TMA. Honoraria: Abcuro, Amazentis, ArgenX, Astellas, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, MDA, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Abata/Third Rock, UCB Biopharma and UpToDate. Royalty: UpToDate |
Ashley Ghiaseddin, MD | Consulting Fee: Alexion Pharmaceuticals (Advisory Board 11/20/22), Consulting Agreement with Neosoma (but have not participated in consulting role as of yet this was just an agreement). Stock Shareholder: Personal stock in Viatris Inc. |
Larry Goldstein, MD, FAHA, FAAN | Other: Data Safety Monitoring Board for Janssen – support to university |
Amy Hessler, DO | Nothing to disclose |
Casey Jeffreys, MD | Consulting Fee: Genentech, Sanofi-Genzyme, EMD Serono Contracted Research: Novartis |
Mohamed Koubeissi, MD, MA, FAAN, FANA, FAES | Speaker’s Bureau: SK Life Sciences Inc |
Laura Lehman, MD | Nothing to disclose |
Sebastian Lopez, MD | Consulting Fee: Horizon/Genentech |
Michael Malinzak, MD, PhD | Nothing to disclose |
Katherine B. Peters, MD, PhD, FAAN | Consulting Fee: Blue Earth Diagnostics, Sapience Therapeutics, Servier Contracted Research: Servier, Biomimetrix, Abbvie, Allergan, Varian, Sapience Therapeutics, Novocure Honoraria: Eisai Stock Option Holder: NuVox |
Aparna Ashutosh Wagle Shukla, MD | Consulting Fee: Sage-Biogen, Supernus, Merz, Acadia Contracted Research: NIH Honoraria: Elsevier, Neurodiem, NIH Other: Tremor Research Group Vice President |
Colleen Stack, MD, MBA | Nothing to disclose |
Kiran Thakur, MD | Nothing to disclose |
Sarah Zallek, MD | Nothing to disclose |
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner or Manager | Reported Financial Relationship |
Lindsay Borvansky | Nothing to disclose |
Ashley Cann | Nothing to disclose |
Alexa DeVantier | Nothing to disclose |
Grace Freeman | Nothing to disclose |
Andrea Funk | Nothing to disclose |
Josh Jones | Nothing to disclose |
Liddy Knight | Nothing to disclose |
Lisa Maher | Nothing to disclose |
Michelle Winokur, DrPH | Nothing to disclose |
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Institute for Patient Access do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
